The global intravenous solution market is predicted to touch USD 11,511.2 million at a 7.69% CAGR over the forecast period (2022-2030), as stated by the latest Market Research Future (MRFR) report. Intravenous solutions are fluids that are delivered into the vein directly. It is the fastest means of delivering fluid replacement and medications throughout the body as they are directly introduced into the circulation. Such intravenous solutions are generally offered to patients whose body nutrients or fluid volume decreases.
Various factors are propelling the intravenous solution market growth. These factors, as stated by the latest MRFR report, include growing incidences of chronic diseases especially cholera, increasing acceptance of vitamin C IV for colorectal cancer, increasing research and development funding, increasing healthcare expenditure, rapidly growing healthcare infrastructure and advancement in technology transpired in medical science. Additional factors pushing market growth include growing population, growing geriatric populace worldwide, investments and seminal efforts transpired to develop an intravenous solution, and improving economic conditions that are enabling access to improved healthcare and quality life.
On the contrary, increasing prices of vitamin C intravenous therapy and strict government regulations are factors that may deter the intravenous solution market growth over the forecast period.
Request Free Sample Copy at:
The MRFR report provides a complete segmental analysis of the intravenous solution market report on the basis of type, nutritional content, and end users.
Based on type, the intravenous solution market is segmented into total parenteral nutrition and peripheral parental nutrition. Of these, the total parenteral nutrition segment will have the largest share in the market over the forecast period.
Based on nutritional content, the intravenous solution market is segmented into parenteral lipid emulsion, vitamins and minerals, carbohydrates, amino acid solution, and others. Of these, the amino acid solution segment will dominate the market over the forecast period.
Based on end users, the intravenous solution market is segmented into ambulatory and home care and hospitals and clinics.
By region, the intravenous solution market report covers the latest trends and growth opportunities across the Asia Pacific, North America, Europe, and the Middle East and Africa. Of these, North America will remain the driving force in the market over the forecast period. This is chiefly due to the high intravenous consumption number of about 750 units of normal saline being used every minute. Canada and the US are the key contributors in the region.
The intravenous solution market in Europe is predicted to have the second-largest share in the market over the forecast period. This is chiefly due to the growing sales of intravenous solutions owing to the corresponding growth of patient pool and rising aging population.
The intravenous solution market in the APAC region is predicted to have a healthy growth over the forecast period. Factors aiding growth in the region include cost advantage, constantly expanding population base, government initiatives, growing private funds, and the emergence of better and high-quality institutions and healthcare infrastructure.
On the flip side, the intravenous solution market in the Middle East and Africa is predicted to have a small share over the forecast period owing to chronic diseases, high health expenditure, and surging healthcare costs.
Leading players profiled in the intravenous solution market report include Grifols S.A. (Spain), Terumo Medical Corporation (Tokyo), Amanta Healthcare (India), Baxter (U.S.), Fresenius Kabi AG (Germany), Braun Melsungen AG (Germany), and ICU Medical, Inc. (U.S.), among others. Various strategies such as research and development, joint ventures, mergers and acquisitions, and product innovations have been adopted by key players to strengthen their foothold in the market.
May 2019: Sihuan Pharmaceutical Holdings Group Ltd is the first company that has received drug registration approval in China for sodium chloride/ceftazidime injection. Currently, this solution is a highly advanced formulation of intravenous solutions that has significant strengths during extreme situations and emergencies. This has been recognized as the most convenient and safest infusion product, which is regarded as a new formulation having excellent development potential in the pharmaceutical domain.
Browse Detailed TOC with COVID-19 Impact Analysis at:
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071